68 related articles for article (PubMed ID: 9531302)
1. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway.
Challita-Eid PM; Penichet ML; Shin SU; Poles T; Mosammaparast N; Mahmood K; Slamon DJ; Morrison SL; Rosenblatt JD
J Immunol; 1998 Apr; 160(7):3419-26. PubMed ID: 9531302
[TBL] [Abstract][Full Text] [Related]
2. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
3. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
4. A RANTES-antibody fusion protein retains antigen specificity and chemokine function.
Challita-Eid PM; Abboud CN; Morrison SL; Penichet ML; Rosell KE; Poles T; Hilchey SP; Planelles V; Rosenblatt JD
J Immunol; 1998 Oct; 161(7):3729-36. PubMed ID: 9759898
[TBL] [Abstract][Full Text] [Related]
5. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions.
Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P
Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031
[TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
7. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
8. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Rohrbach F; Gerstmayer B; Biburger M; Wels W
Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
[TBL] [Abstract][Full Text] [Related]
9. T-cell co-stimulation through B7RP-1 and ICOS.
Yoshinaga SK; Whoriskey JS; Khare SD; Sarmiento U; Guo J; Horan T; Shih G; Zhang M; Coccia MA; Kohno T; Tafuri-Bladt A; Brankow D; Campbell P; Chang D; Chiu L; Dai T; Duncan G; Elliott GS; Hui A; McCabe SM; Scully S; Shahinian A; Shaklee CL; Van G; Mak TW; Senaldi G
Nature; 1999 Dec; 402(6763):827-32. PubMed ID: 10617205
[TBL] [Abstract][Full Text] [Related]
10. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
11. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.
Gerstmayer B; Altenschmidt U; Hoffmann M; Wels W
J Immunol; 1997 May; 158(10):4584-90. PubMed ID: 9144470
[TBL] [Abstract][Full Text] [Related]
12. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
13. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
14. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
15. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.
Chapoval AI; Ni J; Lau JS; Wilcox RA; Flies DB; Liu D; Dong H; Sica GL; Zhu G; Tamada K; Chen L
Nat Immunol; 2001 Mar; 2(3):269-74. PubMed ID: 11224528
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
17. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells.
Marshall KW; Marks JD
J Immunother; 2001; 24(1):27-36. PubMed ID: 11211146
[TBL] [Abstract][Full Text] [Related]
18. Redirecting effector T cells through their IL-2 receptors.
Lustgarten J; Marks J; Sherman LA
J Immunol; 1999 Jan; 162(1):359-65. PubMed ID: 9886407
[TBL] [Abstract][Full Text] [Related]
19. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
